Your browser doesn't support javascript.
loading
Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials.
Begg, Malcolm; Hamblin, J Nicole; Jarvis, Emily; Bradley, Glyn; Mark, Stephen; Michalovich, David; Lennon, Mark; Wajdner, Hannah E; Amour, Augustin; Wilson, Robert; Saunders, Ken; Tanaka, Rikako; Arai, Saki; Tang, Teresa; Van Holsbeke, Cedric; De Backer, Jan; Vos, Wim; Titlestad, Ingrid L; FitzGerald, J Mark; Killian, Kieran; Bourbeau, Jean; Poirier, Claude; Maltais, François; Cahn, Anthony; Hessel, Edith M.
Affiliation
  • Begg M; Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.
  • Hamblin JN; Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.
  • Jarvis E; Biostatistics, GlaxoSmithKline R&D, Stevenage, UK.
  • Bradley G; Computational Biology, Medicinal Science and Technology, GlaxoSmithKline, Stevenage, UK.
  • Mark S; Study Management, Clinical Development, GlaxoSmithKline, Mississauga, ON, Canada.
  • Michalovich D; Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.
  • Lennon M; Nonclinical and Translational Statistics, GlaxoSmithKline, Stevenage, UK.
  • Wajdner HE; Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.
  • Amour A; Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.
  • Wilson R; Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.
  • Saunders K; Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.
  • Tanaka R; Data Management & Strategy, Clinical Development, GlaxoSmithKline, Tokyo, Japan.
  • Arai S; Data Management & Strategy, Clinical Development, GlaxoSmithKline, Tokyo, Japan.
  • Tang T; Pharma Safety, Clinical Development, GlaxoSmithKline, Brentford, Middlesex, UK.
  • Van Holsbeke C; FLUIDDA nv, Kontich, 2550, Belgium.
  • De Backer J; FLUIDDA nv, Kontich, 2550, Belgium.
  • Vos W; FLUIDDA nv, Kontich, 2550, Belgium.
  • Titlestad IL; Department of Respiratory Medicine, Odense University Hospital and University of Southern Denmark, Odense, Denmark.
  • FitzGerald JM; Centre for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada.
  • Killian K; Cardiorespiratory Research Laboratory, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
  • Bourbeau J; Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, QC, Canada.
  • Poirier C; Department of Medicine, Respiratory Medicine Division, University of Montreal, Montreal, QC, Canada.
  • Maltais F; Institut Universitaire de Cardiologie et de Pneumologie de Québe, Université Laval, Quebec City, QC, Canada.
  • Cahn A; Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.
  • Hessel EM; Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Stevenage, UK.
Int J Chron Obstruct Pulmon Dis ; 16: 1621-1636, 2021.
Article in En | MEDLINE | ID: mdl-34113094
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Phosphatidylinositol 3-Kinases / Pulmonary Disease, Chronic Obstructive Type of study: Clinical_trials / Diagnostic_studies Limits: Humans Language: En Journal: Int J Chron Obstruct Pulmon Dis Year: 2021 Type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Phosphatidylinositol 3-Kinases / Pulmonary Disease, Chronic Obstructive Type of study: Clinical_trials / Diagnostic_studies Limits: Humans Language: En Journal: Int J Chron Obstruct Pulmon Dis Year: 2021 Type: Article Affiliation country: United kingdom